Clinical trial · Interventional
Nutritional Supplement for Treating Chemotherapy Induced Neuropathy
Efficacy and Safety of a Tablet Containing Palmitoyethanolamide, Alpha Lipoic Acid, Vitamin B12, Vitamin B6 , Vitamin B1, Nicotinamide, Magnesium, Zinc, Vitamin E, and Superoxide of Dismutase in Individuals Receiving Chemotherapy
NCT07022938CI-TRIAL-00099692completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Administration of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin B12, vitamin B6 , vitamin B1, nicotinamide, magnesium, zinc, vitamin E, and superoxide of dismutase in individuals receiving chemotherapy
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Chemotherapy Induced Pain Neuropathy | — | UNRESOLVED | — |
| Chemotherapy-Induced Peripheral Neuropathy | — | UNRESOLVED | — |
| Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epineuron | Dietary Supplement | — | UNRESOLVED |
| Placebo Tablets | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Epineuron
- description
- Administration of a nutritional supplement with Palmitoylethanolamide (PEA, 300 mg), Superoxide Dismutase (SOD, 70 UI), Alpha Lipoic Acid (ALA, 300 mg), vitamins B6 (1.5 mg), B1 (1.1 mg), B12 (2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2.5 mg) in one tablet
- interventionNames
- Dietary Supplement: Epineuron
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- similar tablet without active ingredients
- interventionNames
- Dietary Supplement: Placebo Tablets
Primary outcomes (2)
- measure
- Neuropathic Pain Symptom Inventory
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed patients with cancer that have not received yet their treatment * Patients that will be treated with platinum agents or taxanes Exclusion Criteria: * Not receiving dietary supplement * Have already neuropathy * Have already started chemotherapy * Patients with uncontrolled diabetes \-- Patients with chronic kidney disease * Patiens with recent cardiovascular incident
References
Publications (0)
Data not yet available
No reference posted for this study.